| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1007: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
|
Medicine details |
|
| Medicine name | rucaparib (Rubraca®) |
| Formulation | 200 mg, 250 mg, 300 mg film-coated tablet |
| Reference number | 3912 |
| Indication | Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy |
| Company | Clovis Oncology Inc |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/12/2018 |
| NICE guidance | |